Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis
This study is currently recruiting participants.
Verified April 2013 by Göteborg University
Sponsor:
Göteborg University
Information provided by (Responsible Party):
Göteborg University
ClinicalTrials.gov Identifier:
NCT01557296
First received: March 16, 2012
Last updated: April 5, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of the study is in subjects with Insulin Treated Diabetes Mellitus type 1 or 2 and gastroparesis:
- validate radiopaque markers with fluoroscopy with gastric scintigraphy method
- study the difference of metabolic control including the frequents of hypoglycaemia, gastrointestinal symptoms, quality of life and nutrition state during dietary treatment of food of small particle size compared with food of large particle size
- validate the radiopaque markers method and measurement of the blood glucose and gastrointestinal symptoms after a test meal, against the gastric scintigraphy
- determine if the function of gastric emptying can be improved after intervention
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetic Gastroparesis |
Dietary Supplement: dietary treatment: food of small particle size Radiation: Validate X-ray diagnostic method. Other: Can the motility be improved Biological: postprandial plasma glucose |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Comparing Treatment With Food of Small Particle Size and Food of Large Particle Size in Subjects With Diabetic Gastroparesis. Evaluation of Diagnostic Methods. Determination of the Motility of Gastric Emptying After Intervention |
Resource links provided by NLM:
Further study details as provided by Göteborg University:
Primary Outcome Measures:
- Metabolic Control - HbA1c [ Time Frame: 22 weeks ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- gastrointestinal symptoms - Questionnaire: Patient Assessment of upper Gastrointestinal Disorders Symptoms, Gastrointestinal Symptom Rating Scale [ Time Frame: 22 weeks ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 50 |
| Study Start Date: | September 2007 |
| Estimated Study Completion Date: | June 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Diabetic diet
Control group. Subjects with Insulin Treated Diabetes Mellitus and Gastroparesis. Diet: Food of large particle size during 20 weeks.
|
Dietary Supplement: dietary treatment: food of small particle size
Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
Other Names:
Radiation: Validate X-ray diagnostic method.
Follow 20 radiopaque markers throw the ventricle by X-ray.
Other Names:
Other: Can the motility be improved
Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
Other Names:
Biological: postprandial plasma glucose
Measure the blood glucose response and gastrointestinal symptoms after a test meal
Other Names:
|
|
Active Comparator: Diet food in small particle size
Intervention group: Subjects with Insulin Treated Diabetes and Gastroparesis. Intervention Diet: Food of small particle size during 20 weeks.
|
Dietary Supplement: dietary treatment: food of small particle size
Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
Other Names:
Radiation: Validate X-ray diagnostic method.
Follow 20 radiopaque markers throw the ventricle by X-ray.
Other Names:
Other: Can the motility be improved
Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
Other Names:
Biological: postprandial plasma glucose
Measure the blood glucose response and gastrointestinal symptoms after a test meal
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- diabetes type 1 or 2 and gastroparesis
- must be able to understand oral and verbal instructions
Exclusion Criteria:
- gastrointestinal surgery
- other gastrointestinal disease
- S-Creatinine >150 umol/L
- mental disease
- cerebral disease
- collagen disease
- untreated endocrine disease
- anticholinergic drugs
- psychopharmacologic drugs
- opiates
- addiction to drugs as alcohol and narcotics
- vegetarian
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01557296
Contacts
| Contact: E A Olausson, postgrad stu | +46 31 342 26 56 | eva.a.olausson@vgregion.se |
Locations
| Sweden | |
| Goteborg Universitet, Sahlgrenska Academy, Sahlgrenska University Hospital | Recruiting |
| Goteborg, Sweden, SE 413 45 | |
| Contact: E A Olausson, postgraduate + 46 31 342 26 56 eva.a.olausson@vgregion.se | |
| Contact: M Simrén, M.D., Ph.D. +46 31 342 10 00 magnus.simren@medicine.gu.se | |
| Principal Investigator: E A Olausson, postgraduate | |
Sponsors and Collaborators
Göteborg University
Investigators
| Study Chair: | Magnus Simrén, M.D., Ph.D. | Inst of Medicine, Sahlgrenska Academy, Göteborg University |
More Information
No publications provided
| Responsible Party: | Göteborg University |
| ClinicalTrials.gov Identifier: | NCT01557296 History of Changes |
| Other Study ID Numbers: | #EMS-5115# |
| Study First Received: | March 16, 2012 |
| Last Updated: | April 5, 2013 |
| Health Authority: | Sweden: Regional Ethical Review Board |
Keywords provided by Göteborg University:
|
Diet Dietary treatment Particle size Gastroparesis Diabetes Mellitus |
Additional relevant MeSH terms:
|
Gastroparesis Stomach Diseases Gastrointestinal Diseases Digestive System Diseases |
Paralysis Neurologic Manifestations Signs and Symptoms |
ClinicalTrials.gov processed this record on June 17, 2013